for females ages 18-42 (full criteria)
Healthy Volunteers
healthy people welcome
at San Francisco, California
study started
estimated completion
Principal Investigator
by Mitchell Rosen, MD
Photo of Mitchell Rosen
Mitchell Rosen



Embryonic aneuploidy is the underlying etiology for the majority of failed implantation and miscarriage. Preimplantation genetic screening (PGS) with transfer of a euploid embryo has been advocated as a strategy for increasing live birth rates with a single embryo transfer. Culturing embryos to the blastocyst stage for trophectoderm biopsy is a requirement for PGS. Several commercially-available single-step embryonic culture media with varying composition have been established for use in the IVF laboratory. Early reports have suggested differences in clinical outcomes, such as aneuploidy and miscarriage rates, with distinct culture media currently in standard use.1,2 However, there have been no clinical trials demonstrating the superiority of any one commercially-available culture media formulation. As a result, clinics use media with varying composition based upon familiarity and cost.

Official Title

Aneuploidy Rates and Morphokinetic Parameters in Sibling Embryos Cultured in Distinct Culture Media


Embryonic Mosaicism Embryo Culture Media Embryo Morphokinetics Infertility EmbryoScope Plus GLOBAL MEDIA SAGE MEDIA


You can join if…

Open to females ages 18-42

All subjects planning blastocyst culture for preimplantation genetic screening (PGS) will be offered enrollment.

Antral Follicle Count (AFC) >8 Male and female partner > 18 years of age

You CAN'T join if...

Female partner age >42 years of age Cleavage stage biopsy


  • University of California San Francisco
    San Francisco California 94158 United States

Lead Scientist at UCSF

  • Mitchell Rosen, MD
    Dr. Mitchell Rosen is a reproductive endocrinology and fertility expert at the UCSF Center for Reproductive Health. He also is director of the UCSF Fertillity Preservation Center, which helps patients with cancer preserve their ability to have children, despite aggressive cancer treatment.


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
Study Type
Last Updated